Quoin Pharmaceuticals Achieves Target Rapamycin Loadings in Topical Delivery Technologies
I'm PortAI, I can summarize articles.
Quoin Pharmaceuticals Ltd. has successfully achieved target loading concentrations for its proprietary topical rapamycin delivery technologies, formulating a lotion with 4% w/w and a dermal patch with 5% w/w rapamycin. The company plans to manufacture clinical trial batches in Q4 2025, with testing starting in H1 2026 for conditions lacking FDA-approved treatments. This marks a significant milestone for Quoin’s topical rapamycin programs.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments